跳至主要内容
临床试验/EUCTR2007-005244-25-DK
EUCTR2007-005244-25-DK进行中(未招募)不适用

Co-treatment with pegvisomant and a somatostatin analogue (SA) in SA-responsive acromegalic patients: impact on insulin sensitivity, glucose tolerance, and pharmacoeconomics

Aarhus University Hospital, Department M0 个研究点开始时间: 2007年10月31日最近更新:
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Acromegalic patients on SA mono therapy, who are considered well-controlled.
  • 1) a serum IGF-I < 2 SDS above the upper normal range or
  • 2) a nadir GH < 0.5 µg/l.
  • 3) Borderline patients, who do not entirely meet these criteria, may be included.
  • This could mean patients who have been on SA mono therapy with appropriate
  • symptom relief for more than 3 years.
  • Written consent
  • Age > 18 years
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range

排除标准

  • Known allergies to IMP
  • Known liver disease
  • Diabetes Mellitus type I

研究者

发起方
Aarhus University Hospital, Department M

相似试验